middle.news
Nyrada Advances Xolatryp to Phase IIa Trial Targeting Heart Attack Damage
8:38am on Wednesday 23rd of July, 2025 AEST
•
Healthcare
Read Story
Nyrada Advances Xolatryp to Phase IIa Trial Targeting Heart Attack Damage
8:38am on Wednesday 23rd of July, 2025 AEST
Key Points
Phase IIa trial planned for 150 STEMI patients in Australia
Xolatryp targets ischemia-reperfusion injury post-PCI
Phase I dosing completed with no adverse safety signals
Trial to evaluate safety and explore efficacy with two dosage levels
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Nyrada (ASX:NYR)
OPEN ARTICLE